Commentary|Videos|December 9, 2025
Decoding Developments in GVHD Management With Drs Salhotra and Negrin
Amandeep Salhotra, MD, and Robert Negrin, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in graft-vs-host disease presented during the 2025 ASH Annual Meeting & Exposition.
Advertisement
Amandeep Salhotra, MD, of City of Hope, and Robert Negrin, MD, of Stanford Medicine, sit down with Chandler Park, MD, FACP, of Norton Cancer Institute, to discuss the latest abstracts in graft-vs-host disease presented during the 2025 ASH Annual Meeting & Exposition.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
An observational analysis showed a long-term OS benefit with Orca-T in adult patients undergoing allogeneic transplantation for hematologic malignancies.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
Revisit Every OncLive On Air Episode From September 2026
3
Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML
4
UTRxMYCN M1-14 Nets FDA Dual Designations in Soft Tissue Sarcoma
5